Hu N - Search Results

1

An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas.

Zhou K, Hu N, Hong Y, Wu X, Zhang J, Lai H, Zhang Y, Wu F. Zhou K, et al. Among authors: hu n. Front Genet. 2022 May 23;13:903393. doi: 10.3389/fgene.2022.903393. eCollection 2022. Front Genet. 2022. PMID: 35677557 Free PMC article.

2

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.

Wu F, Hu N, Li Y, Bian B, Xu G, Zheng Y. Wu F, et al. Among authors: hu n. Cell Oncol (Dordr). 2012 Jun;35(3):175-80. doi: 10.1007/s13402-012-0075-7. Epub 2012 Apr 3. Cell Oncol (Dordr). 2012. PMID: 22476961

3

HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.

Wu F, Zhang J, Liu Y, Zheng Y, Hu N. Wu F, et al. Among authors: hu n. Cell Physiol Biochem. 2013;32(6):1566-76. doi: 10.1159/000356593. Epub 2013 Dec 3. Cell Physiol Biochem. 2013. PMID: 24335195 Free article.

4

Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.

Wu F, Zhang J, Hu N, Wang H, Xu T, Liu Y, Zheng Y. Wu F, et al. Among authors: hu n. Cancer Epidemiol. 2014 Dec;38(6):728-32. doi: 10.1016/j.canep.2014.08.008. Epub 2014 Sep 20. Cancer Epidemiol. 2014. PMID: 25246379

5

Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.

Hu N, Yin JF, Ji Z, Hong Y, Wu P, Bian B, Song Z, Li R, Liu Q, Wu F. Hu N, et al. Cell Physiol Biochem. 2017;44(6):2158-2173. doi: 10.1159/000485955. Epub 2017 Dec 12. Cell Physiol Biochem. 2017. PMID: 29241186 Free article.

6

Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon.

Hong YD, Zhang J, Zhuang M, Li W, Wu PU, Li RT, Hu N, Bian BX, Song ZY, Wu FL. Hong YD, et al. Among authors: hu n. Oncotarget. 2017 Sep 26;8(70):114495-114505. doi: 10.18632/oncotarget.21274. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383097 Free PMC article.

7

Sh-MARCH8 Inhibits Tumorigenesis via PI3K Pathway in Gastric Cancer.

Yin J, Ji Z, Hong Y, Song Z, Hu N, Zhuang M, Bian B, Liu Y, Wu F. Yin J, et al. Among authors: hu n. Cell Physiol Biochem. 2018;49(1):306-321. doi: 10.1159/000492882. Epub 2018 Aug 23. Cell Physiol Biochem. 2018. PMID: 30138931 Free article.

8

MiR-135-5p inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by targeting SMAD3 in breast cancer.

Yang W, Feng W, Wu F, Gao Y, Sun Q, Hu N, Lu W, Zhou J. Yang W, et al. Among authors: hu n. J Cancer. 2020 Sep 9;11(21):6402-6412. doi: 10.7150/jca.47083. eCollection 2020. J Cancer. 2020. PMID: 33033523 Free PMC article.

9

lncRNA OGFRP1 promotes tumor progression by activating the AKT/mTOR pathway in human gastric cancer.

Zhang J, Xu X, Yin J, Tang J, Hu N, Hong Y, Song Z, Bian B, Wu F. Zhang J, et al. Among authors: hu n. Aging (Albany NY). 2021 Mar 19;13(7):9766-9779. doi: 10.18632/aging.202731. Epub 2021 Mar 19. Aging (Albany NY). 2021. PMID: 33744848 Free PMC article.

10

A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer.

Hu N, Li W, Hong Y, Zeng Z, Zhang J, Wu X, Zhou K, Wu F. Hu N, et al. Mol Ther Oncolytics. 2021 Dec 9;24:148-159. doi: 10.1016/j.omto.2021.12.006. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2021. PMID: 35024441 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,963 results

Search Page